Knight Therapeutics Inc (TSE:GUD) – Equities researchers at Cormark increased their Q1 2019 earnings estimates for shares of Knight Therapeutics in a report issued on Thursday, February 21st. Cormark analyst T. Gonsalves now anticipates that the company will post earnings of $0.03 per share for the quarter, up from their previous forecast of $0.02. Cormark also issued estimates for Knight Therapeutics’ FY2019 earnings at $0.12 EPS.
Several other analysts have also recently weighed in on the company. Raymond James reissued an “outperform” rating and set a C$10.25 price target on shares of Knight Therapeutics in a report on Wednesday, January 16th. Bloom Burton reissued an “accumulate” rating on shares of Knight Therapeutics in a report on Friday, November 9th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Knight Therapeutics currently has a consensus rating of “Buy” and a consensus target price of C$10.06.
About Knight Therapeutics
Knight Therapeutics Inc operates as a specialty pharmaceutical company in Canada and internationally. The company is involved in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. Its commercialized products include Movantik to treat opioid induced constipation; Impavido, an alkyllysophospholipid analogue drug for visceral and cutaneous Leishmaniasis; Neuragen to treat pain associated with diabetic and peripheral neuropathy; Synergy family consumer health products; and Flat Tummy Tea, a herbal detox tea.
Further Reading: How to read a candlestick chart
Receive News & Ratings for Knight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.